Summary
Introduction
The main clinical guidelines define COPD by the presence of chronic, almost irreversible, airflow obstruction. The main critic that these guidelines provoke is that they ponder too much the values of the forced spirometry in the diagnosis and the assessment of COPD severity, thus preventing the adequate assessment of the "various faces of the disease". Although a better approach, based on the different phenotypes, without a doubt, increases the complexity of COPD, the currently available information indicates that it is not justified to continue assuming that a classification based exclusively in spirometric criteria is a good classification.
Putting our current knowledge about COPD into perspective, we could say that the continuous exposure to smoking fumes or environmental toxics causes an airflow obstruction, but with marked differences in the inflammatory response, and the damage caused in both the airway and the pulmonary parenchyma. Such damage, in the case of the emphysema, finally leads to destruction.
More than four decades ago, Burrows 1 defined the emphysematous phenotype so as to differentiate it from the bronchitic phenotype. Since the initial description, various observational studies have confirmed the existence of a group of patients with peculiar characteristics, such as the presence of emphysema in imaging techniques, and a decrease in the diffusion test; they are usually patients that tended to produce little sputum, with a lower rate of body mass index (BMI), arterial blood gases best preserved and greater dyspnea. On the contrary, the group with a preponderance of chronic bronchitis usually do not show evidence of emphysema in their chest-X rays and often have well preserved diffusing capacities. It is not infrequent to find exacerbations of this disease associated to bacterial infection data in these patients. 2e5 Finally, there is a group with characteristics shared with bronchial asthma, which has generally been excluded from clinical trials. However, certain studies suggest that these patients constitute a particular phenotype whose evolution presents differentiated characteristics related to a greater concentration of eosinophils in the secretions and in the bronchial mucose. Therefore, from the clinical point of view, it is possible to identify 3 different COPD phenotypes, whose assessment could help get a better understanding and management of the disease.
The objective of this study is to determine the prevalence of each phenotype in a population of stable COPD patients, and analyze the most relevant clinical characteristics in each of them.
Methods
This is an epidemiologic, cross-sectional, observational, and multicenter study performed in 40 pulmonology outpatient services in Spain. There were no interferences on the investigator's decision about the health care or the medical treatment that is most appropriate for the patient. All the necessary data to assess the objectives anticipated in the protocol were registered in a single visit. Each investigator selected, in a consecutive manner, the first 5 COPD patients who met all inclusion criteria and none of the exclusion ones, during a period of two months. Finally 344 COPD patients diagnosed according to GOLD criteria with a significant smoking history (>10 pack years) were recruited. 13 were excluded because they did not have complete information, so that 331 were finally eligible for the study (Table 1) . Table 1 Inclusion and exclusion criteria.
Inclusion criteria
Patients aged 40 or older.
Patients with smoking background whose pack-year index (PYI) is greater than 10.
Patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD) according to GOLD 2007 criteria (post-bronchodilator FEV 1 /FVC (after inhaling 400 mg salbutamol) < 0.70).
Patients receiving treatment and follow-up through pulmonology visits, both in hospitals and in other specialized health centers. Clinical stability in the last month.
Patients who have given their written informed consent.
Exclusion criteria
Patients with current asthma diagnosis.
Patients with a primary pulmonary vascular disease.
Patients presenting, at the time of performing the study, any serious physical and/or mental impediment that would not make the fulfillment of the respiratory function tests possible.
The study was approved by the Clinical Research Ethics Committee of the University General Hospital of Guadalajara (Spain), and all the patients were informed of the characteristics and objectives of such study, giving their written consent for their participation.
Data were collected by means of a standardized case report form including demographic data, characteristics of the chronic obstructive pulmonary disease, comorbidities, and usage of health care resources. The impact of the disease on the patients was analyzed with the following questionnaires: LCADL (London Chest Activity of Daily Living scale), SF12 and CCQ (Clinical COPD Questionnaire), all of them validated to Spanish. The degree of dyspnea was assessed using the Medical Research Council (MRC) validated scale. Table 2 describes the criteria used to assign each patient to a certain phenotype.
Statistical analysis
A descriptive analysis was performed for all study variables, presenting the absolute and relative frequencies in case of qualitative variables, as well as the mean with standard deviation in the case of the continuous variables.
In order to compare independent samples, Pearson's chisquare test was used to compare quantitative variables. Alternatively for qualitative variables Fisher's exact test for 2 Â 2 tables (or the probability ratio in other tables, if necessary) were used. For quantitative variables, the ANOVA test, or its non-parametric equivalent H-KruskaleWallis test, were used. For the analysis between groups, the post-hoc MDS test was used for equal variances, and the Tamhane's T2 test was used for different variances. In all the statistical tests performed, a level of statistical significance below 0.05 was used. The SPSS version 17.0 statistical package was used.
Results
From 331 patients valid for the study the 43.2% (N Z 143) presented an emphysematous phenotype (type 1), 44.7% (N Z 148) were chronic bronchitic (type 2), and the other 12.1% showed a phenotype showing mixed characteristics with asthma (type 3). There were no significant differences in the level of smoking (PYI: 37.8 (11.8), 39.9 (10.3) and 35.6 (10.9)) respectively, in the gasometric values, or in the disease's evolution time among the three groups. Type 1 patients showed lower FEV 1 values, 46.6% (21.1), 55.2% (21.2), and 54.4% (21.8), respectively (p < 0.05) and greater levels of dyspnea (p < 0.05) ( Table 3) .
No significant differences were observed in the percentage of patients who had had at least one exacerbation in the last year (68.8%, 63.9%, 64.9%; p Z 0.25), in the number of exacerbations (p Z 0.56), in the number of visits to emergency room (total and due to COPD), or in the number of hospital admissions (Table 4) .
45.4% of the patients also suffered of arterial hypertension (AHT), 34.0% presented dyslipidemia and 16.9% diabetes. These prevalences were different in the different groups. The subpopulation of patients with phenotype 2 had a greater prevalence of cardiovascular risk factors, except in the case of smoking, where no statistically significant differences were observed. 10.6% of the sample had ischemic heart disease, especially in types 2 and 3 (5.3%, 13.5% and 15% respectively; p Z 0.08). Differences were statistically significant for sleep apnea syndrome (SAS) (4.9%, 23.6% and 12.5%, respectively; p < 0.001) but not for arrhythmias (p Z 0.91), cerebrovascular disease (p Z 0.77), peripheral vascular disease (p Z 0.20), and cardiac failure (p Z 0.58) ( Table 5) .
Excluding short-acting bronchodilators, which were mainly used as rescue medication, the COPD treatment most frequently used was tiotropium (83.7%), followed by the combination of long acting b-2 adrenergic agonists (LABA), and inhaled corticoids (IC). By phenotype, the frequency of patients with a fixed combination of LABA/IC was significantly higher in the subpopulation of phenotype 3 patients (85% versus 69.9 and 64.2% for groups 1 and 2, respectively; p < 0.05), while the medications of the cardiovascular sphere, home ventilation (HF), and CPAP were more frequently used in patients with chronic bronchitic phenotype (Table 6) . No differences were observed in the CCQ specific questionnaire among the different COPD phenotypes. The quality of life using the SF12 generic questionnaire showed that physical health was significantly better in phenotype 3 patients, (p < 0.05). The London Chest Activity of Daily Living (LCADL) scale showed that patients with type 1 phenotype showed a greater sensation of dyspnea while performing everyday life activities (ADL), self-care, and leisure (Table 7) .
Discussion
The main conclusion of our work is that, for an equal degree of smoking, three patients' profiles adjusting to the three classic COPD phenotypes can be identified in clinical practice. Patients with presence of pulmonary emphysema show lower BMI, worse pulmonary function, and greater degree of dyspnea. The main characteristic of the group with chronic bronchitis is that, this is the type of patients showing a greater concentration of comorbidity, specially associated to SAS, and cardiovascular risk factors. This group presented a BMI significantly higher than the other two. Therefore, obesity may constitute a bias explaining, at least partially, the differences in other comorbidities. Finally, group 3 is not large in a general population of COPD, and it is characterized by a greater prevalence in women. The prevalence in this group may vary notably when diagnostic criteria are modified. Although the term phenotype in COPD still generates discrepancy of criteria within the scientific community, in clinical practice it is identified as a characteristic of the disease allowing establishing differences of clinical relevance. 11 This aspect is really important, since the evidence collected during the last years confirms that, for the same FEV 1 , COPD patients can be very different from the clinical, functional, imaging techniques, and evolution course point of view. The ECLIPSE study has recently demonstrated that these differences also extend to exacerbations and FEV 1 deterioration.
12e15 From this point, approaches for phenotype identification in COPD have been very varied. 16 In view of the approach a priori identifying the most relevant phenotypes, certain studies base their strategy in trying to identify all the possible phenotype features and, subsequently, establish groups after performing statistical tests, like factorial analyses and cluster studies. 17e20 However, even both approaches may be complementary, in these cases, most of the phenotype characteristics lack of clinical meaning, in other cases their relevance has not been established and, frequently, they reflect changes associated to different stages of the disease, instead of different profiles of patients. On the contrary, the advantage of using COPD predefined phenotypes is that they are easy to apply in clinical practice, their theory basis is solid, they represent groups of patients with clinical characteristics differentiated regardless functional stage and, frequently, they condition the functional evolution or exacerbation's characteristics. 7, 8, 21 In a study, García-Aymerich et al. 17 analyzed a cohort of 342 patients who were hospitalized for the first time due to COPD exacerbation in 9 Spanish tertiary hospitals. By means of a cluster analysis, they identified three types of patients: group 1 presented a greater functional severity and a worse clinical situation, from the respiratory point of view; group 2 presented less functional deterioration, and group 3 was also characterized by a lower functional deterioration but a greater obesity prevalence, cardiovascular disorders, diabetes, and systemic inflammation. In a certain way, these data are consistent with our results, which also identify, for an equal degree of smoking, a group of patients with greater comorbidity in the cardiovascular sphere and another more symptomatic group with characteristics of emphysema. Due to selection criteria in García-Aymerich's study the group sharing certain common characteristics with asthma could be excluded at entry. Another difference of this study is that our patients were randomly selected from a group of patients visited in external visits. Therefore, these data could be extrapolated to COPD general population assisted in an outpatient environment. In our study, in order to approach COPD heterogenicity, classic concepts were recovered. Despite their relevance, such concepts were abandoned in the last years, especially since the publication of the GOLD guidelines. During the decades previous to the COPD approach, 2 universal phenotypes were used: type A (pulmonary emphysema), and type B (chronic bronchitis). They reflected the two main clinical profiles also based on peculiar features at the image, functional and pathologic level. Subsequently, certain authors considered that this classification was obsolete and was of poor clinical usefulness, promoting a uniform vision of COPD whose classification was based in FEV 1 values. The result was that, after the publication of the Global Initiative for Obstructive Lung Diseases (GOLD) in 2001, key aspects in relation with the disease's heterogenicity have been deleted, giving priority to the simplicity of spirometric values. This way of understanding COPD may have been useful in a certain moment in order to transfer simple messages to big populations, but it currently poses a barrier for progressing in dealing with this disease.
New assessment methods have been incorporated in the risks control, but clinical experience suggests that we must keep on progressing in the characterization of patients' profiles, since various aspects related to the risk, such as comorbidity or exacerbations, may be conditioned by the patient's profile. Although a degree of overlapping of the different lesions in airways and pulmonary parenchyma is high, it is clear that the presence of different injuries in the airways and pulmonary parenchyma, and the differences observed from the clinical point of view, make it reasonable to recover this approach, although it may be necessary to subsequently validate their real utility in longitudinal studies. 22, 23 In fact, this relevance was already observed in classical studies. 24 The information obtained in the last years, which goes from basic aspects to the positioning of certain drugs in the treatment of these patients, invites us to reassess the classic phenotypes.
25e29 Surprisingly, despite the evident differences in clinical characteristics of patients, the amount of exacerbation was similar in the three groups. However, the simple numeric assessment of exacerbations has a limited value, since there are important limitations in the current definition of COPD exacerbation. 30 The present study does not allow for the identification of characteristics of all exacerbations, but this should be a primary objective in any study with a longitudinal design, also including the possible role of cardiovascular disorders and other diseases associated in the deterioration of patients and the hospital admittances.
31e33 On the other hand, since they are patients with a complete treatment for their disease, it cannot be excluded that the absence of differences in this section may be, at least, conditioned by a greater efficiency of the treatment in those patients with a greater risk of exacerbations. Although there are data in the literature relating the presence of chronic bronchitis with a greater risk of exacerbations, 34 our data belonging to a treated population, do not allow for an adequate assignation of the type of patient by their exacerbations' history. In fact, a greater risk of exacerbations has been described when there exists a greater amount of emphysema, when chronic bronchitis is associated, and when common characteristics with asthma exist. 5, 6, 35 These findings invite us to pose different phenotypes of exacerbations, whose treatment and prevention should be individualized according to baseline characteristics of each patient. 7, 8, 17 Only a controlled study previously analyzing the patients' profiles could give us an answer to this question.
The prescription pattern observed is not surprising, since the current clinical guidelines recommend that the pharmacological treatment should be based mainly on FEV 1 values and on the symptoms. The recent experience in the development of roflumilast indicates that such approach may not be correct, since the previous identification of patients' profiles allows achieving a greater benefit when the drug is administered to the most adequate patient, and when its use is prevented in those patients who are unlikely to benefit from it. 25, 26 This approach is equally valid for drugs such as inhaled corticoids and can be key in the development of new drugs whose efficacy in certain groups of patients may be concealed when a general COPD population is analyzed.
The impact on life quality is difficult to assess in a crosssectional study like ours, where most of the patients are receiving a great number of drugs. However, the different clinical expression observed in each group is reflected, both in the LCADL and in the SF12, with predominant variables, mainly respiratory (dyspnea, etc.), in patients with a predominance of emphysema characteristics.
The main limitation of our work is that it is a crosssectional study. Therefore, clinical relevance of these data should be prospectively assessed in a longitudinal study. Another limitation is that the population selected comes from patients visiting the pulmonology outpatient services, therefore the results are not necessarily likely to be extrapolated to general population. Finally, the criteria established to define the groups may seem arbitrary, but the differentiation of COPD-asthma phenotype is similar to that used in the COPDgene study. 6 Likewise, the criteria to differentiate the group with a predominance of chronic bronchitis and the group with emphysema, although they do not allow the establishment of strict cut-off points, they do allow to refine patients' profiles where one of these components is predominant.
Conclusions
In a general population of COPD patients, most of them adapt to chronic bronchitis and emphysema phenotype. Emphysematous patients normally show a worse pulmonary function and a greater dyspnea, although there were no differences in the use of hospital health care resources. The greater comorbidity in group 2 patients may require specific strategies in this subgroup of patients. These data support the abandonment of a homogeneous handling of COPD patients, and they invite us to develop clinical and investigation strategies based on patients' profiles.
